No abstract is provided for this article.
This paper describes the various levels of information within an intelligent support system for the design of injection moulds. The design system integrates CAD/CAM, database and expert system tools. It allows the designer to define an injection mould in terms of...
Selective laser sintered parts in polyamide are increasingly being used in functional applications. The monotonic properties of these parts are well-known and documented. The cyclic material properties, on the other hand, are largely unknown. Therefore, in this paper a systematic analysis is made of fatigue properties and failure mechanisms of selective laser sintered parts subjected to fluctuating loading in tension/compression. Both plain and notched specimens are produced along perpendicular building directions. The fatigue behaviour of these parts is analysed and compared to injection moulded samples. In addition, the influence of the test frequency and the notch manufacturing method is studied.
7-Deazaxanthine (7-DX) was recently identified as the first purine derivative with pronounced inhibitory activity against Escherichia coli thymidine phosphorylase (TP) and angiogenesis. In order to "freeze" the enzyme in an open, inactive conformation, a novel multi-substrate analogue inhibitor of TP, containing an alkyl phosphonate moiety covalently linked to 7-DX, was synthesized. The prototype compound TP65 (9-(8-phosphonooctyl)-7-deazaxanthine) (at 250 microM) completely inhibited TP-induced formation of microvascular sprouts from endothelial cell aggregates in a three-dimensional fibrin gel. In the chick chorioallantoic membrane assay, TP caused a dose-dependent stimulation of angiogenesis, which was completely inhibited by 250 nmol TP65. This dose proved to be non-toxic for the developing chick embryo. TP65 thus emerges as a potent and specific inhibitor of TP and TP-induced angiogenesis, which opens new perspectives for multi-substrate analogue inhibitors of TP as potential anti-cancer agents and as inhibitors of angiogenesis and of diseases with enhanced expression of TP.
For the treatment and/or prevention of HIV (human immunodeficiency virus) and HBV (hepatitis B virus) infections, 15 tenofovircontaining drug preparations have been commercialized: TDF (tenofovir disoproxil fumarate) and TAF (tenofovir alafenamide) for the therapy of HIV and HBV infections;
Abstract Modified 1,2,6-thiadiazine dioxide acyclonucleosides were synthesized using the silylation method. All the compounds were tested as antiviral agents in a wide variety of assay systems. With two compounds, some activity (20, 35 and 14 μg/mL, respectively) was noted against herpes simplex virus, human cytomegalovirus and varicella-zoster virus.